Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
University Hospital, Lille
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
63High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07625800CT.gov Switch to Ofatumumab and Level of Immunoglobulins | — | Not Yet Recruiting | — | — | — |
NCT07546110CT.gov An Open-Label, Single-Arm Clinical Study to Evaluate the Safety and Preliminary Efficacy of CD20 Monoclonal Antibody Combined With NK042 Cell Injection in the Treatment of Multiple Sclerosis (MS). | — | Not Yet Recruiting | — | — | — |
NCT06444113CT.gov Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT06121349CT.gov WOE of Anti-CD20 Therapies | — | Completed | — | — | — |
NCT07353216CT.gov Exploring the Efficacy and Safety of Ofatumumab in Patients With Relapsing Multiple Sclerosis (RMS) and Its Impact on Serum Neurofilament Light Chain (sNfL) Levels | — | Recruiting | — | — | — |
NCT06167642CT.gov Retinal Atrophy and Neurofilament Light Chain in People With Multiple Sclerosis Taking Ofatumumab | — | Enrolling By Invitation | — | — | — |
NCT05414487CT.gov Effects of Ofatumumab Treatment on Immune Cells and Meningeal Lymphatic Drainage in Patients With Demyelinating Diseases | — | Unknown | — | — | — |
NCT04926818CT.gov Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis | — | Active Not Recruiting | — | — | — |
NCT05688436CT.gov A Study to Learn More About The Safety of Diroximel Fumarate (VUMERITY®) in Participants Who Took it During Pregnancy And About the Health of Their Babies | — | Active Not Recruiting | — | — | — |
NCT04788615CT.gov Open Label Randomized Multicenter to Assess Efficacy & Tolerability of Ofatumumab 20mg vs. First Line DMT in RMS | — | Completed | — | — | — |
Show 4 more trialsShow fewer
NCT04676555CT.gov Time and Motion Study for Ocrelizumab and Ofatumumab Administration in Relapsing Multiple Sclerosis | — | Completed | — | — | — |
NCT03560739CT.gov A 12 Week Randomized Open Label Parallel Group Multicenter Study to Evaluate Bioequivalence of 20 mg Subcutaneous Ofatumumab Injected by Pre-filled Syringe or Autoinjector in Adult RMS Patients | — | Completed | — | — | — |
NCT01457924CT.gov Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis | — | Completed | — | — | — |
NCT00640328CT.gov Ofatumumab Dose-finding in Relapsing Remitting Multiple Sclerosis (RRMS) Patients | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Multiple Sclerosis
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humax-Cd20 (this asset) | University Hospital, Lille | Approved | BB · 64 |
| Ocrelizumab | Polpharma Biologics International AG | P4 | BBB |
| Cladribine | University Hospital, Strasbourg, France | P4 | BBB |
| Teriflunomide | Sanofi | P4 | BBB |
| Nabiximols | Jazz Pharmaceuticals | P4 | BBB |
| Fampridine | MGH Institute of Health Professions | P4 | BBB |
| Natalizumab | Biogen | P4 | BB |
| Fingolimod | Biogen | P4 | BB |
| Methylphenidate | Johns Hopkins University | P3 | BB |
+42 more in the Multiple Sclerosis cohort
Other indications for Humax-Cd20
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| B-Cell Chronic Lymphocytic Leukemia | — | P4 | BBB · 78 |
| Relapsing-Remitting Multiple Sclerosis | — | P4 | BBB · 74 |
| Diffuse Large B-Cell Lymphoma | — | P3 | BB · 67 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humax-Cd20 in Multiple Sclerosis. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/humax-cd20-multiple-sclerosis
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →